蛋白S作为治疗靶点
蛋白S(PS)是关键的抗凝物质,并通过与Tyro3和MerTK受体酪氨酸激酶相互作用参与细胞信号传导。靶向PS(增强或抑制其活性)已成为调节凝血和炎症的有前景策略。严重PS缺乏导致弥散性血管内凝血和暴发性紫癜等危及生命的状况,杂合性缺乏与静脉血栓栓塞风险升高相关。PS增强纳米抗体在小鼠模型中显示出强效抗血栓作用,而PS抑制正被用于治疗血管性血友病和血友病等出血性疾病,其中一种单克隆抗体在血管性血友病患者1/2期试验中显示出安全性和初步疗效。
要点
- 严重PS缺乏(纯合或复合杂合)可导致弥散性血管内凝血和暴发性紫癜等危及生命的状况。
- 杂合性PS缺乏与静脉血栓栓塞风险升高相关。
- PS增强纳米抗体在小鼠模型中显示出强效抗血栓作用,支持其作为新型安全抗凝策略的概念验证。
核心结论
- 靶向PS(增强或抑制其活性)已成为调节凝血和炎症的有前景策略,支持继续开发PS靶向疗法,用于血栓性和出血性疾病以及减轻慢性出血状况下的组织损伤。
研究设计与样本
- 综述,未报告具体检索范围。
主要发现
- PS增强纳米抗体在小鼠模型中显示出强效抗血栓作用。
- 靶向PS的单克隆抗体和小干扰RNA在临床前模型中显示出安全性和有效性。
- 一种单克隆抗体在血管性血友病患者1/2期试验中显示出安全性和初步疗效。
- PS通过Tyro3和MerTK受体信号对关节和骨组织发挥保护作用。
- PS抑制正被用于治疗血管性血友病和血友病等出血性疾病。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Protein S (PS) is a key anticoagulant with additional roles in cell signaling through its interaction with Tyro3-Axl-MerTK family receptor tyrosine kinases Tyro3 and MerTK. Therapeutic targeting of PS-either enhancing or inhibiting its activity-has emerged as a promising strategy to modulate coagulation and inflammation. Approaches include nanobodies, monoclonal antibodies, and RNA interference, aiming to restore hemostatic balance or prevent bleeding, depending on the clinical context. Severe PS deficiency (homozygous or compound heterozygous) causes life-threatening conditions such as disseminated intravascular coagulation and purpura fulminans. Heterozygous deficiency is associated with an elevated venous thromboembolic risk. These insights highlight the need for tailored modulation of PS activity. A PS-enhancing nanobody has demonstrated potent antithrombotic effects in murine models, establishing proof-of-concept for a novel, safe anticoagulant strategy. Conversely, PS inhibition is being pursued to treat bleeding disorders such as von Willebrand disease and hemophilia. Both monoclonal antibodies and small-interfering RNAs targeting PS have shown safety and efficacy in preclinical models. Notably, a monoclonal antibody has demonstrated safety and preliminary efficacy in a phase 1/2 trial in patients with von Willebrand disease. Beyond coagulation, PS exerts protective effects on joint and bone tissues via Tyro3 and MerTK receptor signaling, further broadening its therapeutic potential. These findings support the continued development of PS-targeted therapies, with implications for both thrombotic and bleeding disorders, as well as for mitigating tissue damage in chronic bleeding conditions.
引用
- Prince Eladnani R, Diab R, Angelillo-Scherrer A, et al. Protein S as a therapeutic target. J Thromb Haemost. 2025. PMID: 41197807. doi:10.1016/j.jtha.2025.10.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。